Engineered Skeletal Muscle Units for Repair of Volumetric Muscle Loss in the Tibialis Anterior Muscle of a Rat by VanDusen, Keith W. et al.
Engineered Skeletal Muscle Units for Repair of Volumetric
Muscle Loss in the Tibialis Anterior Muscle of a Rat
Keith W. VanDusen, MS,1 Brian C. Syverud, MS,2 Michael L. Williams, BS,1
Jonah D. Lee, PhD,1 and Lisa M. Larkin, PhD1,2
Volumetric muscle loss (VML) is the traumatic, degenerative, or surgical loss of muscle tissue, which may
result in function loss and physical deformity. To date, clinical treatments for VML—the reflected muscle flap
or transferred muscle graft—are limited by tissue availability and donor site morbidity. To address the need for
more innovative skeletal muscle repair options, our laboratory has developed scaffoldless tissue-engineered
skeletal muscle units (SMUs), multiphasic tissue constructs composed of engineered skeletal muscle with
engineered bone-tendon ends, myotendinous junctions, and entheses, which in vitro can produce force both
spontaneously and in response to electrical stimulation. Though phenotypically immature in vitro, we have
shown that following 1 week of implantation in an ectopic site, our muscle constructs develop vascularization
and innervation, an epimysium-like outer layer of connective tissue, an increase in myosin protein content,
formation of myofibers, and increased force production. These findings suggest that our engineered muscle
tissue survives implantation and develops the interfaces necessary to advance the phenotype toward adult
muscle. The purpose of this study was to evaluate the potential of our SMUs to restore muscle tissue to sites of
acute VML. Our results indicate that our SMUs continue to mature in vivo with longer recovery times and have
the potential to repair VML sites by providing additional muscle fibers to damaged muscles. We conclude from
this study that our SMUs have the potential to restore lost tissue volume in cases of acute VML.
Introduction
Multiple pathological conditions, including trau-matic injuries, congenital defects, postoperative dam-
age, and degenerative myopathies, can lead to volumetric loss
of skeletal muscle tissue. Volumetric muscle loss (VML) is
the loss of muscle tissue that exceeds the body’s capacity for
self-repair, resulting in impaired muscle function, and in
many cases, physical deformity.1,2 While many musculo-
skeletal traumas may be endogenously repaired over time
through the myogenic potential of satellite cells, more severe
cases of VML overwhelm this native repair mechanism,
creating a need for surgical intervention.3 The diversity of
VML cases along with the functional and metabolic demands
of muscle tissue complicates surgical repair, so while several
repair strategies exist, all have significant limitations.1 The
primary treatment strategies involve muscle flap transposition
or autologous tissue transfer.4–9 Although each procedure
type has demonstrated some success, both are limited by
donor site morbidity and lack of available graft tissue. Thus, a
demand exists for exogenous graft muscle tissue, prompting
tissue engineering approaches to be increasingly investigated
as potential strategies for VML treatment.
Since Vandenburgh’s first work in 1988 suspending
myotubes in a collagen gel and Dennis’s first work in 2000
generating scaffoldless three-dimensional (3D) constructs
that produced a physiological response similar to native
muscle,10–12 there continues to be significant research done in
the area of skeletal muscle tissue engineering. While no
laboratory has successfully yet engineered muscle that is
functionally or phenotypically equivalent to adult skeletal
muscle,13–17 our group has developed a reproducible tech-
nique for engineering scaffold-free 3D skeletal muscle tissue
constructs with functional myotendinous and neuromuscular
interfaces, and has recently initiated implantation stud-
ies.18,19–23 These skeletal muscle units (SMUs) contract
spontaneously, producing *50mN of force in vitro, and when
stimulated electrically, they produce an average maximum
isometric force of 192– 41mN in vitro.18 Previously, we have
shown that following only 1 week of implantation in an ec-
topic site, the maximum isometric force increased 286% to an
average of 549– 103mN.18 When their maximal tetanic for-
ces are normalized to cross-sectional area (CSA), the en-
gineered muscle produces a specific force of 1945 N/m2, one
of the highest recorded specific forces generated by an en-
gineered 3D skeletal muscle. We hypothesize that implanting
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our SMUs for greater periods of time will further increase
their contractile strength.
For restoration of function following VML injury, several
interfaces must be established between host and graft tis-
sues. For optimal force transmission, the implanted muscle
constructs must have a means of anchoring to native bone so
they may translate their contractile force production into
movement. Our multiphasic SMUs meet this requirement
via in vitro development of myotendinous junctions and
entheses between their engineered muscle and bone/tendon
components. These features give the constructs structural in-
tegrity similar to native muscles. Previous research from our
lab has shown that similarly engineered multiphasic bone-
ligament constructs reorganize and mature to develop native-like
entheses after implantation in vivo.24 Additionally, as a highly
complex and metabolically demanding tissue, skeletal muscle
relies on advanced vascular networks for blood perfusion and
neurotization for maintenance of structure and contractile con-
trol. Previous research in our lab indicates that within a single
week of implantation, our skeletal muscle constructs achieve
vascularization and begin to develop innervation.18
Our laboratory has developed a rat model for creating and
repairing acute VML by removing a longitudinal section,
approximately one-third of the total width, from the lateral
aspect of the tibialis anterior (TA) muscle. This model suits
the geometry of our SMUs and, by leaving most of the distal
TA tendon intact and drilling a bone tunnel in the lateral
tibial head, it provides anchoring sites for the attachment of
the bone-tendon anchors. Using our VML model in rats
(n = 6), we replaced *10% of the lost tissue volume with
our SMUs and allowed for 28 days of recovery. The purpose
of this study was to examine the potential of our SMUs to
repair an acute 30% VML injury in 1 month and to examine
advancement in the structure and function of our constructs
with respect to muscle fiber size, vascularization, innerva-
tion, and construct force production. We hypothesized that
the in vivo environment would promote integration of the
SMU bone anchor into the native bone and the tendon an-
chor into native tendon and encourage advancement of the
muscle phenotype beyond what was previously observed
after a single week of implantation.
Materials and Methods
Animal model and animal care
Tissue engineering studies were conducted using soleus
muscles and bone marrow from 120- to 150-g female Fi-
scher 344 rats, obtained from Charles River Laboratories,
Inc. (Wilmington, MA) and Harlan Laboratories (Haslett,
MI). All animals were acclimated to our colony conditions
for 1 week, that is, light cycle and temperature prior to any
procedure. The animals were fed Purina Rodent Chow 5001
laboratory chow and water ad libitum. The harvested tissues
were used as an allogenic cell source of muscle precursor
cells and bone-marrow-derived stem cells for production of
muscle and bone tissues that were later implanted into the
host animals. The host animals were also female Fischer 344
rats. All surgical procedures were performed in an aseptic
environment, with animals in a deep plane of anesthesia
induced by isoflurane or intraperitoneal injections of sodium
pentobarbital (65 mg/kg). Supplemental doses of pentobar-
bital were administered as required to maintain an adequate
depth of anesthesia. All animal care and animal surgery pro-
cedures were in accordance with The Guide for Care and Use
of Laboratory Animals25 and the protocol was approved by
the University Committee for the Use and Care of Animals.
Preparation of media
Unless otherwise indicated, all solutions and media were
prepared and stored at 4C prior to isolation and culture of
cells and warmed to 37C in a heated bead bath immediately
prior to use. Muscle growth medium (M-GM) contained
30 mL F-12 Kaighn’s Modification Nutrient Mixture (cat.
No. 21127-022; Gibco BRL, Carlsbad, CA), 12.5 mL Dul-
becco’s modified Eagle’s medium (DMEM; cat. No. 11995-
065; Gibco BRL), 7.5 mL fetal bovine serum (FBS; cat. No.
10437-028; Gibco BRL), 2.4 ng/mL basic fibroblast growth
factor (bFGF; cat. No. 100-18B; Peprotech, Rocky Hill, NJ),
and 0.5 mL antibiotic-anti-mycotic (ABAM; cat. No. 15240-
062; Gibco BRL). Muscle differentiation medium (M-DM)
was composed of 33 mL M199 (cat. No. 11150-059; Gibco
BRL), 14 mL DMEM, 3.3 mL FBS, 50mL insulin-transferrin-
selenium-X (cat. No. I1884; Sigma-Aldrich, St. Louis, MO),
0.5 mL ABAM, and 36.2 mL 50 mM ascorbic acid 2-phos-
phate. Transport medium (TM) consisting of Dulbecco’s
phosphate-buffered saline (DPBS [pH 7.2]; cat. No. 14190-
144; Gibco BRL), with 2% ABAM, was used to transfer
freshly isolated tissues from the surgical suite to the tissue
culture facilities for isolation. Bone growth medium (B-GM)
contained 40 mL DMEM and 10 mL FBS, supplemented with
1% ABAM, 6 ng/mL bFGF, and 5 ng/mL dexamethasone
(cat. No. D4902; Sigma-Aldrich). Bone differentiation me-
dium (B-DM) contained 46.5 mL DMEM and 3.5 mL FBS,
supplemented with 1% ABAM, 0.13 mg/mL asc-2-phos,
0.05 mg/mL L-proline (cat. No. P0380; Sigma-Aldrich), and
5 ng/mL dexamethasone.
Preparation of construct dishes
Muscle constructs were fabricated in individual 60-mm
plates, as described previously.18,22 Each plate was coated
with 5 mL Sylgard (type 184 silicon elastomer; Dow Che-
mical Corp., Midland, MI) and allowed to cure for 3 weeks
prior to use. One to 7 days prior to use, each sylgard-coated
plate was coated with laminin at 1 mg/cm2 per plate (Natural
Mouse Laminin, cat. No. 23017-015; Gibco BRL) sus-
pended in 4 mL DPBS, and left to dry for 24–48 h. Residual
salt crystals were dissolved and removed by rinsing the
plates with 4 mL DPBS. The plates were then filled with
3 mL M-GM and decontaminated with UV light (wave-
length 253.7 nm) for 60 min and placed in a 37C/5% CO2
incubator for up to 3 days prior to plating the muscle cells.
Preparation of tissue-engineered bone-tendon anchors
Bone marrow from Fischer 344 rats was removed under
aseptic conditions. Isolated bone marrow cells were plated
in 100-mm tissue culture plates (BD Falcon, Franklin Lakes,
NJ) in 8 mL B-GM for 5 days and then passaged and re-
plated. After four passages, the cells were plated in 100-mm
tissue culture plates at a density of 1.3 million cells per
plate. They were left to grow in 8 mL B-GM for 5 days
before being shifted to B-DM for 2 days. At this stage, the
confluent bone monolayers began to delaminate from the
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tissue culture plate. The monolayers were collected, pinned
in cylindrical forms into sylgard-coated dishes and fed B-
DM, and left for 5–10 days prior to being cut into 5-mm
sections to be used as engineered bone anchors for construct
implantation. The anchors were then pinned onto the de-
veloping muscle monolayers.
Dissection of muscle and isolation of muscle cells
Both soleus muscles were removed under aseptic condi-
tions and sterilized in 70% ethanol. Prior to dissociation, the
muscles were incubated in 5 mL of TM for 5 min. The
muscles were then minced using a razor blade, placed under
ultraviolet light for 15 min in 15 mL of Ham’s F12 (cat. No.
11765-047; Gibco BRL), and then added to a dissociation
solution consisting of 32 U dispase (1.8 U/mg, cat. No.
17105-041; Gibco BRL) and 2390 U type IV collagenase
(239 U/mg, cat. no. 17104-019; Gibco BRL) in 20 mL of
Ham’s f12 nutrient media. The mixture was then kept at
37C with agitation for 90 min to allow the minced muscle
to dissociate. The solution was then poured through a 100-
mL filter and centrifuged. The dissociation solution was
aspirated off and the cells were resuspended in M-GM.
Construct formation
The cell isolation mixture was plated in M-GM at a
density of 400,000 cells per 60-mm plate. After the initial
seeding, the plates were left undisturbed for 5 days, and
subsequently fed M-GM every 2 days until they became
*70% confluent. At this point, the cells were lifted from the
dish with 0.5 mL of 0.25% trypsin (Gibco BRL), mixed into
M-GM, and seeded again at the same density. They were
then fed M-GM every 2 days until the plates were 100%
confluent and elongating myotubes began to form a network
across the base of the plate. At this point, 5-mm tissue-
engineered bone anchors were pinned onto the cell mono-
layers 2.5 cm apart and the media was changed to M-DM,
which the plates were fed every 2 days. After approximately
a week on M-DM, the monolayers were delaminated from
the plates, rolling into cylindrical muscle constructs, held at
length by the engineered bone anchors.
SMU contractile measurements
Contractile properties of the constructs were measured
prior to implantation into host animals. The protocol for
measuring contractility of engineered muscle constructs has
been described previously.26 Briefly, the pin on one end of
the construct was freed from the Sylgard and attached to a
force transducer with canning wax. For field stimulation of
the entire construct, platinum wire electrodes were placed
along either side of the SMU. The temperature of the con-
struct was maintained at 37C, using a heated aluminum
platform. Passive baseline force was measured as the average
baseline passive force preceding the onset of stimulation.
Twitches were elicited using a single 2.5-ms pulse at 10, 30,
60, and 90 mA, whereas maximum tetanic force was deter-
mined using a 1-s train of 2.5-ms pulses at 90 mA and 10, 20,
40, 60, and 80 Hz. Data files for each peak twitch force and
peak tetanic force trace were recorded and subsequently an-
alyzed, using LabVIEW 2009 data acquisition software.
Surgical procedures
Each Fischer 344 SMU host rat was anesthetized using
isofluorane. An incision was made along the left lower
hindlimb exposing the TA, and a longitudinal cut was made
to remove *30% of the TA volume (Fig. 1A, B). A 0.9-mm
tunnel was drilled into the proximal tendon insertion site on
FIG. 1. A pictorial representation of the VML and SMU implantation procedure. (A) One-third of the left TA muscle was
removed, (B) leaving an *33% muscle volume deficit. (C) A single SMU (D) was implanted into the VML site, with one of its
bone anchors inserted into a tibial bone tunnel and the other tendon end sutured to the distal TA tendon left from muscle volume
removed. The tibial and distal TA tendon attachment sites are marked by black arrows in D. A branch of the peroneal nerve with
its vasculature was isolated and sutured to the mid-belly of the SMU, marked by the white arrows in B and D. SMU, skeletal
muscle unit; TA, tibialis anterior; VML, volumetric muscle loss. Color images available online at www.liebertpub.com/tea
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the tibia, and the peroneal nerve distal to the innervation of
the extensor digitorum longus was transected along with its
associated vasculature, and routed to the area of VML. A
single SMU (Fig. 1C) was then placed in the repair site, with
one of its bone ends pulled into the tibial bone tunnel and
sutured in place on the periosteum, and the other end of the
construct sutured to the remaining distal tendon of the TA.
The transected nerve branch was then sutured to the SMU
using 9-0 suture (Fig. 1D). The surgical site was then closed
with surgical staples and Carprofen was administered fol-
lowing each procedure at a dose of 5 mg/kg every 12 h for
48 h postsurgery. The staples were removed after 10 days.
TA contractile measurements
Following 28 days of recovery, in vivo contractile prop-
erties were measured as described by Larkin et al.27 Briefly,
the host and control rats were anesthetized with an injection
of sodium pentobarbital (65 mg/kg) with supplemental in-
jections given to maintain an adequate level of anesthesia
throughout the procedures. Isometric contractile properties
of the TA muscles were measured in situ. In anesthetized rats,
the whole TA muscle was isolated from surrounding muscle
and connective tissue using great care not to damage the nerve
and/or blood vessels during the dissection. A 2–0 silk suture
was tied around the distal tendon, and the tendon was severed.
The animal was then placed on a temperature-controlled
platform warmed to maintain body temperature at 37C. The
hindlimb was securely tied to a fixed post with wire at
the knee. The distal tendon of the TA muscle was then tied to
the lever arm of a servomotor (model 305B; Aurora Scien-
tific). A continual drip of saline warmed to 37C was ad-
ministered to the TA muscle to maintain its temperature and to
prevent desiccation. The muscle was activated by stimulation
of the sciatic nerve using a bipolar platinum wire electrode.
The voltage of single 0.2-ms stimulation pulses was adjusted
to give a maximum isometric twitch. Subsequently, muscle
length was adjusted to the optimal length (Lo) at which twitch
force was maximal. With the muscle held at Lo, 300-ms trains
of stimulus pulses were applied at increasing stimulation
frequencies until the maximum isometric tetanic force (Po)
was achieved. Measures of Lo were taken and used to calcu-
late functional CSA as described previously.26
After all force measurements were completed, muscles
were removed, and deeply anesthetized rats were euthanized
by administration of a pneumothorax and the TA muscles
were trimmed of their tendons, blotted, and weighed. Muscle
fiber length was calculated by multiplying Lo by a ratio of
fiber length to TA muscle length described previously.28 Total
muscle CSA was calculated by dividing the muscle mass (mg)
by the product of muscle fiber length (mm) and the density of
mammalian skeletal muscle, 1.06 g/cm2. Specific Po (N/cm
2)
was calculated by dividing Po by total CSA for each muscle.
Immediately after muscle mass was measured, muscles were
coated in tissue-freezing medium (Triangle Biomedical Sci-
ences, Durham, NC), frozen in isopentane cooled by dry ice,
and stored at - 80C until analyzed for histology.
Histochemical and immunohistochemical
analyses of SMU structure
Following measures of mechanical function, the frozen
samples of repaired and contralateral TA were sectioned at
12mm, mounted on Superfrost Plus microscopy slides, and
used for histological analysis. Sections were stained for
general morphology observations with hematoxylin and
eosin (H&E). For immunohistochemical analysis, frozen
sections were fixed with ice-cold methanol for 10 min and
rinsed with DPBS. The sections were submerged for 15 min
in 0.05% Triton X-100 (Sigma-Aldrich) in DPBS (PBST)
and blocked with PBST containing 3% bovine serum al-
bumin (PBST-S, cat. No. A2153-10g; Sigma-Aldrich) at
room temperature. The sections were then incubated
overnight at 4C with the primary antibodies diluted in
PBST-S. Immunofluorescent staining with specific anti-
bodies was performed to detect the presence of myosin
heavy chain (MF-20 mouse monoclonal antibody, 1:20 di-
lution, cat. No. ALD-58, obtained from the Developmental
Studies Hybridoma Bank, Iowa City, IA), a-actinin (mouse
monoclonal antibody, 1:200 dilution, cat. No. A7752; Sig-
ma, St. Louis), collagen type 1 (rabbit polyclonal antibody,
5 mg/mL, cat. No. AB755P; Millipore, Billerica, MA), pan-
axonal neurofilament (mouse monoclonal antibody, 1:300
dilution, cat. No. SMI-312R; Covance, Inc., Princeton NJ),
CD-31 (mouse monoclonal antibody, 1:100 dilution, cat.
No. ab24590; Abcam, Cambridge, MA), paxillin (rabbit
polyclonal antibody, 1:100 dilution, cat. No. ab2264; Ab-
cam), a-bungarotoxin (1:20 dilution, cat. No. B-1601; Mo-
lecular Probes, Carlsbad, CA), polymorphonuclear
leukocytes (PMNs; rabbit polyclonal antibody, cat. No.
AIAD31140, 1:100 dilution; Accurate Chemical, Westbury,
NY), F4/80 (biotin-conjugated mouse monoclonal antibody,
1:200 dilution, cat. No. MCA497B; AbD Serotec, Raleigh,
NC), and fibroblast specific protein 1 (FSP1; rabbit poly-
clonal antibody, 1:200 dilution; Neomarkers, Fremont, CA).
Following three washes in PBST, the sections were incubated
in 1:500 dilutions of with Alexa Fluor anti-mouse, anti-
chicken, or anti-rabbit antibodies (Life Technologies, Carls-
bad, CA) for 3 h at room temperature. Following three washes
in PBST, the sections were fixed in Prolong Gold with DAPI
and coverslipped. The sections were examined and photo-
graphed with an Olympus microscope and cross-sections of
the constructs were analyzed using the Image J software
package.
Statistical analysis
Values are presented as mean – standard error. Measure-
ments of significant differences between means were per-
formed using JMP statistical analysis software. Means were
compared using one-way analysis of variance tests with
Tukey post-hoc analyses. Differences were considered sig-
nificant at p < 0.05.
Results
Muscle masses and contractile properties
Following a 28-day recovery period, the body masses and
the repaired and contralateral TA muscle masses were
compared to determine the effects the SMUs had on overall
TA muscle mass and health of the animal. The average body
masses of the rats from the control, acute VML, and repaired
TA groups were 170– 2.4, 166– 2.8, and 170– 3.7 g, re-
spectively, and were not statistically different (Fig. 2A),
indicating that the graft and surgical procedure had no
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impact on the growth of the animals. The average TA
masses of the control, acute VML, and repaired TA groups
were 357 – 5.2, 264 – 7.5, and 276– 10.5 mg, respectively
(Fig. 2B). The difference between the average control TA
mass and the average repaired and acute VML TA masses
was statistically significant ( p= 0.0002 and p< 0.0001, re-
spectively). Normalized to the average control TA mass, the
acute VML TAs had an average mass deficit of 26%– 2.1%,
while the repaired TAs had an average mass deficit of
22% – 2.8% of the average control TA mass (Fig. 2C). The
average masses of the repaired and acute VML TAs were
not significantly different.
The SMUs had a mean preimplantation force of 121 – 9.6
mN. Following the recovery period, the SMUs were thor-
oughly integrated into the host TAs and could not be se-
parated and force-tested independent of the host muscle
without damaging the construct tissue and compromising
the contractile data. The maximum forces produced by the
FIG. 2. (A) A comparison of the average animal body
masses in control, acute VML, and repaired VML groups
shows no significant differences, indicating that direct
comparisons of TA mass and force production can be drawn.
(B) A comparison of TA masses shows a significant mass
deficit in both the acute VML and the repaired TA groups in
comparison to the control group ( p< 0.0001 and p = 0.0002,
respectively). The difference in average TA mass between
these groups was not significant, indicating that the SMUs
did not appreciably restore muscle volume to the repaired
TAs in 28 days. (C) Normalized to the average control TA
mass, the damage to the acute VML TAs constituted a
26%– 2.1% mass deficit and the repaired TAs were found to
have a 22%– 2.8% mass deficit. Error bars indicate standard
error. {Statistical difference from control group.
FIG. 3. (A) A comparison of the average maximum forces
produced by the repaired TAs and the control TAs reveals a
24%– 3.0% force production deficit (p= 0.0012), indicating
that the SMUs did not fully restore force production to the
repaired TAs after 28 days of recovery. The acute VML group
suffered a 38%–3.5% force production deficit ( p<0.0001),
which may be largely attributed to hemorrhaging and damage
from the VML procedure. (B) Specific forces for each group
indicate that the control and repaired TAs fall within the ex-
pected range for healthy skeletal muscle, while the acute VML
group produced a decreased specific force (p=0.0040) likely
due to the compromised muscle integrity. Error bars indicate
standard error. {Statistical difference from control group;
*statistical difference from acute VML group.
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repaired muscles averaged 24% – 3.0% less than those
produced by the control muscles (p = 0.0012), indicating
that the SMUs did not fully restore maximum force pro-
duction to the injured TAs (Fig. 3A). The specific forces of
both repaired and control TAs were calculated and the
difference in specific forces between the groups was not
found to be significant (Fig. 3B). This indicates that the
graft did not adversely affect the function of the repaired
TA muscle.
Morphology of muscle constructs
H&E staining of the repaired and control TA sections was
performed to analyze the general morphology of the SMUs
after 28 days of recovery (Fig. 4A). The CSA of the repaired
tissue was measured and found to be 1.24%– 0.03% of the
CSA of the muscle removed.
In addition, it was noted that the myogenic cells within
the SMUs developed into small but distinct muscle fibers at
an average of 181– 26 fibers per graft. The CSAs of the
newly formed muscle fibers found within the grafted area
were 118– 6 mm2, or 8.0% of the mean CSA of control
native TA fibers, which averaged 1473 – 45 mm2 (Fig. 4C).
The difference between the average graft and native muscle
fiber CSA was statistically significant ( p < 0.0001).
Immunohistochemistry
Immunostaining was used to visualize the presence of
myosin heavy chain and laminin in the SMUs (Fig. 4B).
Myosin heavy chain content confirmed the identity of these
structures as muscle fibers, while immunostaining for laminin
indicated that each SMU fiber has a laminin-rich extracellular
matrix, much like the endomysium surrounding individual
native fibers. Immunostaining for macrophage and granulo-
cyte markers (F4/80 and PMN, respectively) was performed
to determine the presence of these cells in the graft region
(Fig. 4A); however, no evidence of immune cell infiltration
was observed (data not shown). Immunostaining for the fi-
broblast marker FSP1 indicated that a number of cells in the
area of regeneration are fibroblasts (Fig. 4D).
Immunostaining for a-actinin (Fig. 5A) indicated that the
construct fibers are aligned along the length of the SMUs
and developed advanced sarcomeric organization (Fig. 5B),
similar to that found in native muscle. Immunostaining for
CD-31 indicated the presence of an advanced capillary net-
work throughout the construct tissue, similar to that in native
skeletal muscle (Fig. 6A, B). Immunostaining for paxillin
(Fig. 7) at the junction between muscle fibers (myosin heavy
chain) and tendon (Collagen 1) showed the development of
myotendinous junctions in the implanted SMUs.
FIG. 4. (A) Cross-sectional area (CSA) analysis of construct morphology indicates that after 30 days in vivo, the SMUs
developed small but defined muscle fibers. (B) The construct fibers featured laminin-rich extracellular matrices (Laminin,
green) and expressed myosin heavy chain (MF-20, red). (C) Analysis of the CSAs of the construct (n= 6 constructs) and
native control TA (n = 8) fibers indicates that the construct fibers’ average CSA is 118– 6 mm2, or 8.0% of the average CSA
of the native fibers in the control TAs ( p < 0.0001). (D) Staining for fibroblast specific protein 1 (FSP1, green) indicates that
the numerous cells near the graft muscle fibers (MF-20, red) are fibroblasts. Error bars indicate standard error. {Statistical
difference from the native muscle fibers. Color images available online at www.liebertpub.com/tea
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Immunostaining for neurofilament and costaining with
tetramethylrhodamine-conjugated a-bungarotoxin indicated
the presence of numerous neural branches throughout the
graft tissue originating from the grafted nerve and traversing
along the length of the construct. High concentrations of
neuromuscular junctions were found in the region where the
grafted nerve interfaces with the SMUs (Fig. 8A). Coloca-
lization of the a-bungarotoxin and neurofilament stains in-
dicated that the nerve branches terminate at neuromuscular
junctions, forming a neuromuscular interface in the con-
struct tissue (Fig. 8B).
Bone tunnel repair
After removal of the TA muscles, the tibial bones were
collected and cleaned for inspection of the bone tunnels.
Figure 9 shows a comparison of an unaltered control tibia
(Fig. 9A), an unrepaired tibia showing the location of the
0.9-mm tibial head bone tunnel (Fig. 9B), and repaired tibia
with the bone tunnel fully healed (Fig. 9C). Five of the six
repaired tibias showed complete healing of the tibial head
and integration of the proximal SMU bone anchor into the
native bone tissue. The sixth tibia showed only partial healing
of the bone tunnel during recovery (Fig. 9D); however, this
did not appear to impact development of the SMUs.
Discussion
The purpose of this study was to examine the effects of
in vivo implantation on the maturation of our SMUs and to
evaluate their potential to treat VML. We hypothesized that
the 28-day implantation period would promote advancement
of the construct muscle phenotype toward that of an adult
skeletal muscle, including increases in fiber size, sarcomere
organization, and vascular/neural interfacing. We also hy-
pothesized that the SMUs would partially restore lost mus-
cle volume and begin to contribute to overall muscle force
production.
After 28 days of exposure to the in vivo environment, our
constructs exhibited structural advancements from their
in vitro state. Perhaps the most significant alteration to the
SMU phenotype was the formation of distinct and uniaxial
FIG. 5. (A) Immunohistochemical analysis of longitudinal SMU sections with an anti-a-actinin antibody indicates that
after 28 days in vivo, the SMU muscle fibers are closely aligned along the length of the construct, mimicking the
organization of native muscle tissue. (B) The same image at a greater magnification indicates that the SMU muscle fibers
also developed advanced sarcomeric structure. Color images available online at www.liebertpub.com/tea
FIG. 6. (A, B) Immunohistochemical staining for CD-31 (red) and Collagen 1 (green) indicates the presence of a well-
developed capillary network throughout the engineered muscle tissue. As in native muscle, most of the vasculature is
aligned with the muscle fibers. Color images available online at www.liebertpub.com/tea
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aligned muscle fibers encased in an extensive extracellular
matrix, similar in structure to native skeletal muscle. The
fiber alignment marks a significant advancement in the
structural organization beyond that observed in many other
skeletal muscle tissue engineering approaches, which dem-
onstrate in vivo increases in graft muscle content, but fall
short of developing true, aligned muscle fibers. Consider-
able research effort has been directed toward promoting
in vitro fiber alignment in engineered muscle tissue. These
methods include utilizing scaffolds with aligned pores29 or
microgrooves30 and culture bases with aligned fibronectin
stripes31 to encourage common orientation of developing
myotubes in vitro. While these strategies have found con-
siderable success, our SMUs also exhibit fiber alignment
without the limitations posed by scaffolds, thus offering an
alternative approach for skeletal muscle engineering. Our
scaffoldless technology prevents stress-shielding of the en-
gineered muscle fibers, allowing for uniaxial loading of the
SMUs. This encourages proper fiber alignment and opti-
mizes force production and transmission to tendon and bone.
FIG. 7. Immunohistochemical staining for myosin heavy chain (red) and Collagen type 1 (green) shows the structure of
the SMU muscle to tendon interface. Inset: The presence of paxillin (green) at this interface and its colocalization with the
graft muscle fibers (red) demonstrate the similarity of this interface to a native myotendinous junction. Color images
available online at www.liebertpub.com/tea
FIG. 8. Immunohistochemical staining for pan-axonal neurofilament (green) and acetylcholine receptors (alpha-bun-
garotoxin, red) indicates that after 28 days of implantation, the engineered muscle becomes highly innervated and forms
neuromuscular junctions. (A) Regions in the engineered muscle near the grafted nerve show high densities of colocalized
motor neurons and acetylcholine receptor clusters, indicating development of a neuromuscular interface between the host
and the graft muscle. (B) These neuromuscular junctions were found at the termini of neural branches within the SMUs.
Color images available online at www.liebertpub.com/tea
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Analysis of the explanted TAs did not indicate any evi-
dence of immune response to the grafts at the time of ex-
amination. This was expected, as no immune response was
found in previous engineered muscle implantation studies
after one week of in vivo development. Numerous fibro-
blasts were found dispersed among the regenerating muscle
fibers, which may indicate remodeling of the graft extra-
cellular matrix to accommodate the developing muscle fi-
bers. We hypothesize that these fibroblasts originated from
the graft tissue, which is partially composed of fibroblasts
prior to implantation. The nature of SMU development and
remodeling with respect to native cell infiltration and turn-
over will be examined in future studies.
Examination of the repaired tibial bone indicated that
the bone-tendon anchors of our SMUs integrated into the
native bone of the tibial heads as they healed, forming
entheses with the native bone tissue and myotendinous
junctions with the engineered muscle. The development of
these tendon-like interfaces between the host and graft
tissues is significant to the application of our skeletal
muscle engineering technology; rather than repairing only
sections of damaged muscle, our SMUs can also provide
restoration of damaged bone-tendon-muscle interfaces.
Further, because they develop these interfaces, mimicking
the gross structure of native muscles, they are able to ef-
fectively transmit force between anchoring structures as
native muscles do. This would potentially allow the SMUs
to be used for full muscle replacement in addition to
muscle repair.
Promising research has been performed on in vitro neu-
rotization and neuromuscular interfacing of engineered
muscle19,32 and in vivo work had demonstrated the necessity
of innervation to the functional advancement of engineered
muscle tissue.33 Of particular interest is the innervation and
formation of neuromuscular junctions, an obstacle to tissue
engineering strategies for muscle repair, and a critical step
for contractile control of engineered muscle graft tissue.34
Our immunohistochemical stains show numerous nerve fi-
bers branching from the grafted nerve into our engineered
muscle, with individual nerve branches extending through-
out the grafted region and terminating at clusters of ace-
tylcholine receptors, demonstrating the in vivo development
of neuromuscular junctions within the SMUs.
Though recent research on the innervation of graft muscle
tissue has shown development of neuromuscular junctions
after 8 weeks, complete restoration of muscle function was
not achieved even after 12 weeks.34 Past studies in our lab
have also demonstrated that reinnervation of the rat medial
gastrocnemius muscle after denervation is an extensive
process that may require over 3 months before maximum
recovery is achieved.35 Thus, despite the promising inner-
vation and neuromuscular junction formation observed in
our SMUs, it is likely that their neuromuscular interfaces
had not yet fully matured after only 28 days in vivo. We
hypothesize that given greater time to recover, the devel-
oping muscle fibers within our SMUs will increase their size
and strength toward that of native muscle fibers. This study
was intended to assess the survival and early development of
FIG. 9. Photographs of (A) an unaltered left tibia, (B) a tibia with a 9-mm-diameter bone tunnel in the tibial head for
anchoring an SMU, (C) and a tibia from a rat with an implanted SMU show that the bone anchor of the SMU fully repaired
the 9-mm surgical anchor hole and integrated into the native tissue of the tibial head. (D) A photograph of one of the
repaired tibias shows incomplete healing of the bone tunnel.
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our SMUs when used to treat VML, while ongoing studies
with recovery times of 3 months and beyond will focus on
the maturation of the SMU neuromuscular systems and their
subsequent functional contributions to repaired muscles.
In conclusion, though our SMUs did not fully restore
muscle mass or force production in our VML model, they
survived in vivo and exhibited significant advancement in
phenotype, indicating that further investigation of their use
for partial or even entire small muscle repair is warranted.
Future studies will focus on longer implantation durations,
larger tissue replacement volumes, and entire muscle re-
placements.
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